Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
May 17, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
May 12, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
April 15, 2021 16:39 ET
|
Adamis Pharmaceuticals Corporation
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
April 13, 2021 16:03 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory...
Adamis Pharmaceuticals Provides an Update on ZIMHI™
April 12, 2021 07:00 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its...
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
August 31, 2020 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and...
UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 11:54 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
February 22, 2018 08:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple...
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
December 11, 2017 07:30 ET
|
Mucodel Pharma LLC
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel...